Yerlikaya, HalisSöğütçü, NilgünYılmaz, Engin DenizLaçin, Sahin2024-04-242024-04-2420212146-26312587-053Xhttps://doi.org/10.5505/kjms.2021.58751https://search.trdizin.gov.tr/yayin/detay/487030https://hdl.handle.net/11468/28384Aim: Colorectal cancer (CRC) is one of the most common and mortal diseases and prognostic factors have a crucial role in stratifying patients. We aimed to evaluate the importance of CDX2 expression, serum CEA level, and tumor sidedness in CRC patients. Material and Method: Patients diagnosed with colorectal cancer between September 2014 and December 2019 were included in the study. Serum CEA level, primary tumor bias, CDX2 expression and other demographic characteristics were recorded as variables. All study analyzes were performed using SPSS version 22 statistical software (IBM Corporation). Results: 152 patients with CRC were included, 64 (42.1%) of patients were female and 88 (57.9%) of patients were male, the median age of patients was 55 (range 18–93). The median survival of patients with serum CEA level <3.5ng/ml, and the patients with CEA level >3.5 ng/ml was 35.1 and 26.6 months, respectively, and the difference between groups was a statistically significant (p=0.006). There was a positive correlation between disease stage and serum CEA level, metastatic patients had higher serum CEA level than non-metastatic patients (p=0.009). In terms of tissue CDX2 expression, eleven patients (7.2%) had CDX2 expression negative, 136 (89.5%) of patients had CDX2 expression positive. The difference between OS rates of patients according to CDX2 expression status was not significant (p=0.7). Despite the longer survival of patients with left-sided than right-sided, the difference was not significant, the median OS was 67.6 and 29.7 months, respectively (p=0.3). The median follow-up time was 24.1 months. Conclusion: The serum CEA level was found as a clear prognostic factor for CRC patients. Additionally, CDX2 expression positive and left-sided primary tumors had longer survival as reported in the literature. Also, our patient stratification model based on tumor sidedness and serum CEA level obtained promising outcomes but need to be confirmed by larger and prospective trials.eninfo:eu-repo/semantics/openAccessArticle11227528148703010.5505/kjms.2021.58751